About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
 
  About Us
  Research & Development
  Biopharmaceuticals
  Branded Formulations
  Financial Results
  - Investor Presentation
  - Chairman's AGM 2016 Speech
  - Annual Reports
  Facilities Virtual Tour
  Downloads
  - Biocon Profile
  - CMD Profile
  - Video Gallery

 Annual Report 2016

 

 Biocon Malaysia

 Biocon Academy

Email:
admissions@bioconacademy.com

 

     
 

Biocon Ltd., Asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics. We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.

The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.

As an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of small molecules APIs & formulations and complex biologics – both novels and biosimilars - including monoclonal antibodies (MAbs), rh- Insulin and insulin analogs.

Our global scale capacities for manufacturing high quality, affordable biologics have positioned us as the world’s fourth largest insulins producer, enabling us to address the growing needs of diabetes patients across the globe. As one of the leading oncology companies in India, we have brought safe, efficacious and affordable medicines for cancer to cater to the needs of patients, caregivers and medical practitioners in the country.


read more...

 
   
   
   
 

 

 

Q2FY17 Highlights
Stock Update
 
 
 
 
 
 

  Latest Press Release
 

 Dec. 09, 2016:
 Biocon Features in Asia IP  Elite 2016 List


 Nov. 29, 2016:
 Biocon's Novel Diabetes  Education Initiative for  Medical Practitioners  'ABIDE' Awarded by RSSDI
 

 


  Media Coverage
 

November, 2016:
EMA accepts Biocon's review plea for drug

October, 2016:
Biocon is betting big on biosimilars: Mazumdar-Shaw

Contact

Contact


Contact

Contact

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved